ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (
ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (darolutamide), supported by clinical collaboration with Bayer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.